[
  {
    "ts": null,
    "headline": "AbbVie to Present at the 43rd Annual J.P. Morgan Healthcare Conference",
    "summary": "AbbVie (NYSE: ABBV) will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. Management will participate in a fireside chat at 10:15 a.m. Central time.",
    "url": "https://finnhub.io/api/news?id=5530916a8db87628b9a23ff730096fd28ac9cffc14e7f399da2831d6da350f03",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736427600,
      "headline": "AbbVie to Present at the 43rd Annual J.P. Morgan Healthcare Conference",
      "id": 132350363,
      "image": "https://media.zenfs.com/en/prnewswire.com/a5eaa0af5f515703fe951de405417559",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. Management will participate in a fireside chat at 10:15 a.m. Central time.",
      "url": "https://finnhub.io/api/news?id=5530916a8db87628b9a23ff730096fd28ac9cffc14e7f399da2831d6da350f03"
    }
  },
  {
    "ts": null,
    "headline": "Buy The Dip: SCHD's Top Holdings Show That It Is Way Too Cheap",
    "summary": "Discover why SCHD is a clear buy with a look at its top 10 holdings and why they make it an attractive investment opportunity right now.",
    "url": "https://finnhub.io/api/news?id=3b68bfa866454efa7af7ce3949bd40eddda968966891067ff52185ad91becf1d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736424000,
      "headline": "Buy The Dip: SCHD's Top Holdings Show That It Is Way Too Cheap",
      "id": 132349330,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1289941019/image_1289941019.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Discover why SCHD is a clear buy with a look at its top 10 holdings and why they make it an attractive investment opportunity right now.",
      "url": "https://finnhub.io/api/news?id=3b68bfa866454efa7af7ce3949bd40eddda968966891067ff52185ad91becf1d"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie's Stock Is Unfairly Cheap",
    "summary": "The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, showcasing resilience and growth.",
    "url": "https://finnhub.io/api/news?id=5b77ae12b9f39389e2d6d324dd3200c7eb7d38ae0cbd993eb98ce31dc2c1c46e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736415354,
      "headline": "AbbVie's Stock Is Unfairly Cheap",
      "id": 132347547,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2175801616/image_2175801616.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, showcasing resilience and growth.",
      "url": "https://finnhub.io/api/news?id=5b77ae12b9f39389e2d6d324dd3200c7eb7d38ae0cbd993eb98ce31dc2c1c46e"
    }
  }
]